|
Listen to this text  |
Noah Medical at present introduced constructive accuracy outcomes from a examine of its Galaxy System surgical robotic platform.
San Carlos, California-based Noah Medical designed Galaxy and its equipment to supply bronchoscopic visualization and entry. These capabilities present diagnostic and therapeutic procedures in affected person airways.
The system options superior imaging applied sciences that present real-time location updates for doubtlessly cancerous lesions. Noah stated in a information launch that it designed the expertise to enhance tool-in-lesion and diagnostic yield.
Galaxy acquired FDA clearance in March of this yr. Earlier in April, Noah Medical raised $150 million to assist its surgical robotic platform.
The MATCH examine examined the “tool-in-lesion” accuracy of the Galaxy System. Noah Medical printed outcomes for evaluation within the Journal of Bronchology & Interventional Pulmonology.
About the outcomes from the Noah Medical MATCH examine
According to a information launch, the examine demonstrated that the Galaxy’s TiLT Technology achieves 100% profitable navigation to lesion. It additionally demonstrated 100% diagnostic yield and 95% tool-in-lesion accuracy. TiLT Technology options built-in tomosynthesis and augmented fluoroscopy.
“The Galaxy System was designed in collaboration with physicians, for physicians,” stated Jian Zhang, Noah Medical founder and CEO. “These results help to validate the advanced design and technology of our system. This important publication comes on the heels of the recent FDA clearance of Galaxy and the first-in-human trial now underway in Australia. The Galaxy System is on a rapid path to commercialization in pursuit of our mission to enhance the quality of life for patients globally.”
MATCH aimed to evaluate the tool-in-lesion accuracy in peripheral lung nodules, confirmed by CBCT in a porcine mannequin. Noah stated the outcomes provide essential insights as a result of present robotic platforms stay liable to CT-to-body divergence. The firm stated confirming a excessive fee of tool-in-lesion might allow Galaxy to extend the speed of definitive analysis.
Principal investigator Dr. Krish Bhadra known as Galaxy “a new category of image-guided robotics.” Bhadra, out of CHI Memorial Hospital in Chattanooga, Tennessee, stated the examine “gets us one step closer” to the purpose of fixing CT-to-body divergence in interventional pulmonology.
Editor’s Note: This article was republished from MassDevice, a sister publication of The Robot Report.